BioMarin Names New Chief People Officer With Extensive Biotech HR Background
BioMarin Pharmaceutical appointed Cara Bauer as Executive Vice President and Chief People Officer effective October 5, 2026, succeeding retiring Amy Wireman. Bauer brings over 25 years of human resources experience from leadership roles at major biotechnology and technology firms including Kyverna Therapeutics, Kite/Gilead, Amgen, and Netflix. The company emphasized Bauer's track record in building and scaling organizations during periods of growth and transformation.
Bauer's appointment marks a leadership transition at BioMarin following the retirement of Amy Wireman, who spent nearly 14 years at the company and oversaw organizational growth during the launch and commercialization of multiple therapies. Wireman's tenure also included management of the recent integration of Amicus Therapeutics following an early-2026 acquisition. Bauer's educational background in industrial and organizational psychology, combined with executive experience across diverse sectors including biotechnology, entertainment, and consumer technology, positions her to address talent development and organizational scaling during a period of expanded operations.
Leadership appointments in drug development firms may influence how companies attract and retain scientific talent during competitive periods in biotechnology. Bauer's varied industry experience could shape recruitment strategies and workplace culture at a company developing treatments for rare genetic diseases. Such human resources changes can indirectly affect organizational capacity to advance clinical pipelines and commercialize therapies, potentially impacting timelines for patients awaiting treatment options for rare conditions.